Clinical trial
A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
NCT02094573 is registered in ClinicalTrials.gov with Ariad Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
- Lead sponsor
- Ariad Pharmaceuticals
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- June 4, 2014
- Completion date
- February 27, 2020
- Enrollment
- 222 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.